A significant shift in our drug policy has occurred, as the regulators allow the availability of psilocybin hallucinogens for therapeutic purposes. Until now, these substances were severely restricted, but a mounting body of research suggests they could offer benefits for mental health conditions like anxiety. The new policy represents a substantia